Day: June 10, 2025

Quest PharmaTech Announces Opposition to OQPBIOM’s Acquisition of AdBioTech

Written by Customer Service on June 10, 2025. Posted in Mergers And Acquisitions.

EDMONTON, Alberta, June 10, 2025 (GLOBE NEWSWIRE) — Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced today that Quest was not informed or consulted, opposes and will not support the recently announced acquisition by privately held South Korea-based OQPBIOM Inc. (“OQM”) of a controlling interest in AdBioTech Co., Ltd. (“AdBioTech”), a public company listed on KOSDAQ in South Korea. OQM has announced that AdBioTech is the corporate vehicle through which it wishes to pursue the funding and advancement of its immunotherapy assets. As announced by Quest on June 2, 2025, as a result of the conversion of bonds, Quest has acquired a 26.25% share ownership interest in...

Perseus Mining Announces 5 Year Gold Production Outlook

Written by Customer Service on June 10, 2025. Posted in Public Companies.

Perth, June 11, 2025 (GLOBE NEWSWIRE) — Perth, Western Australia/ June 11, 2025/ Perseus Mining Limited (ASX/TSX: PRU) (Company) is pleased to provide its gold production and All-In Site Cost (AISC) outlook for the five-year period from FY26 to FY30 inclusive for its portfolio of mines located in Ghana, Côte d’Ivoire and Tanzania. The Five-year Operating Outlook incorporates the updated planning outlook for each of Perseus’s three existing operations based on planning assumptions reflecting current operating conditions. It also takes into account Final Investment Decisions (FID) for the CMA underground mining operation at the Yaouré Gold Mine in Côte d’Ivoire (see ASX announcement “Perseus Mining takes Final Investment Decision on CMA underground project at Yaouré” dated 28 January 2025), as well as the development of the Nyanzaga...

D-BOX Reports Record Full-Year Revenue and Profitability for Fiscal 2025

Written by Customer Service on June 10, 2025. Posted in Earnings Releases And Operating Results.

Royalty-driven Model delivers Strong Margin Expansion and Cash Generation; Leadership Transition positions Company for Next Phase of Growth All dollar amounts are expressed in Canadian currency(1) Please refer to “non-IFRS and other financial performance measures” in this press release Fiscal 2025 HighlightsRecord total revenues of $42.8 million, up 8% vs. FY 2024 Record royalties of $11 million, up 27% vs. FY 2024 Adjusted EBITDA1 of $7.3 million, or 17% of total revenues, up 9 pts vs. FY 2024 Net profit of $3.9 million, up 254% year-over-year, or fully diluted EPS of $0.02 Cash flow from operating activities of $7.3 million Liquidity of approximately $16 million as of March 31, 2025Fourth Quarter HighlightsTotal revenues of $8.6 million, down 15% vs. Q4 2024 Royalties of $2.2 million, up 5% year-over-year Adjusted EBITDA...

Stingray Reports Fourth Quarter and Full-Year Results for Fiscal 2025

Written by Customer Service on June 10, 2025. Posted in Earnings Releases And Operating Results.

Sustained Momentum with a Third Year of Diversified Growth and Solid Financial Strength Fourth Quarter HighlightsOrganic growth of 16.1% year-over-year in Broadcast and Recurring Commercial Music Revenues; Revenues increased 14.8% to $96.0 million in the fourth quarter of 2025 from $83.7 million in the fourth quarter of 2024; Net income totaled $7.7 million, or $0.11 per share, in the fourth quarter of 2025 compared to a Net loss of $46.3 million, or $0.67 per share, in the same period in 2024; Adjusted EBITDA(1) grew 19.0% to $35.0 million in the fourth quarter of 2025 from $29.4 million in the fourth quarter of 2024. Adjusted EBITDA(1) by segment was $28.1 million, or 43.6% of revenues for Broadcasting and Commercial Music, $8.6 million or 27.3% of revenues for Radio, and $(1.7) million for Corporate; Adjusted Net income(1) improved...

Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements

Written by Customer Service on June 10, 2025. Posted in Public Companies.

Not for dissemination in the United States of America VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) — Aja Health and Wellness Inc. (“Aja” or the “Company”) (TSXV:Aja) announces that it is getting closer to filing its annual audited financial statements for the financial year ending December 31, 2024, including the related management’s discussion and analysis and certifications from the CEO and CFO (the “Required Annual Filings“). On May 6, 2025, the Alberta Securities Commission (the “ASC“) issued a management cease trade order (the “MCTO“) because the Company was unable to file the Required Annual Filings in time to meet the April 30, 2025 filing deadline. Aja previously announced that the delay in filing the Required Annual Filings was due to the determination...

argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease

Written by Customer Service on June 10, 2025. Posted in Public Companies.

ALKIVIA data demonstrate significant improvement in muscle strength and physical function in myositis patients treated with efgartigimod RHO data show efgartigimod achieved sustained reduction in autoantibodies and improved functional outcomes in patients with Sjogren’s disease; program granted U.S. FDA Fast Track designation argenx committed to new therapeutic areas in rheumatology with ongoing Phase 3 studies in myositis (ALKIVIA) and Sjogren’s disease (UNITY)June 11, 2025, 12:01 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of positive results from Phase 2 studies evaluating VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and...

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Written by Customer Service on June 10, 2025. Posted in Public Companies.

Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net SalesOTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) — Philochem AG (“Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer....

17 Education & Technology Group Inc. Announces First Quarter 2025 Unaudited Financial Results

Written by Customer Service on June 10, 2025. Posted in Earnings Releases And Operating Results.

BEIJING, June 11, 2025 (GLOBE NEWSWIRE) — 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced its unaudited financial results for the first quarter of 2025. First Quarter 2025 Highlights1Net revenues were RMB21.7 million (US$3.0 million), compared with net revenues of RMB25.5 million in the first quarter of 2024. Gross margin was 36.2%, compared with 38.4% in the first quarter of 2024. Net loss was RMB30.9 million (US$4.3 million), compared with net loss of RMB56.1 million in the first quarter of 2024. Net loss as a percentage of net revenues was negative 142.8% in the first quarter of 2025, compared with negative 219.9% in the first quarter of 2024. Adjusted net loss2 (non-GAAP), which excluded share-based compensation expenses...

Vocus and Telesat announce multi-year Telesat Lightspeed terrestrial infrastructure and services contract

Written by Customer Service on June 10, 2025. Posted in Public Companies.

MELBOURNE, Australia and OTTAWA, Canada, June 10, 2025 (GLOBE NEWSWIRE) — Vocus, Australia’s specialist digital infrastructure provider, and Telesat (Nasdaq and TSX: TSAT), one of the world’s most innovative satellite operators, today announced that Vocus will build Australia’s first Telesat Lightspeed Low Earth Orbit (LEO) Landing Station. Vocus will construct and operate the new Landing Station in New South Wales, Australia and provide fibre connectivity to Telesat’s point of presence (PoP), connecting Telesat’s advanced LEO satellite constellation, called Telesat Lightspeed, to terrestrial networks, providing secure, low-latency satellite services across the region. “As a leading provider of Landing Stations and fibre network solutions, Vocus is an ideal partner to deliver the resilient, scalable...

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Written by Customer Service on June 10, 2025. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the...

Day: June 10, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals